The effects of liraglutide on both hypereosinophilic insulin allergy and the characteristics of anti-insulin antibodies in type 2 diabetes mellitus: A case report

Journal of Medical Case Reports

Volumn 10, Issue 1, 2016, Pages

  Hirai, Hiroyuki ^a   Ogata, Emi ^a   Kikuchi, Nobuyuki ^a   Kohno, Teruyuki ^a   Machii, Noritaka ^a   Hasegawa, Koji ^a   Watanabe, Tsuyoshi ^a   Satoh, Hiroaki ^a  

^a FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Anti insulin immunoglobulin G antibodies; Human insulin specific immunoglobulin E; Hypereosinophilia; Insulin allergy; Liraglutide

Indexed keywords

C PEPTIDE; GLIMEPIRIDE; GLUCOSE; HEMOGLOBIN A1C; IMMUNOGLOBULIN E; INSULIN; INSULIN ANTIBODY; INSULIN ASPART; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; INSULIN RECEPTOR ANTIBODY; LIRAGLUTIDE; METFORMIN; VOGLIBOSE; ANTIDIABETIC AGENT;

AGED; ANTIBODY BLOOD LEVEL; ANTIBODY COMBINING SITE; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; BLOOD SAMPLING; BODY WEIGHT; CASE REPORT; DISEASE DURATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EOSINOPHIL COUNT; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HOSPITAL DISCHARGE; HUMAN; HUMAN TISSUE; HYPEREOSINOPHILIA; IMMUNOGLOBULIN BLOOD LEVEL; INJECTION SITE INDURATION; INJECTION SITE PRURITUS; INSULIN ALLERGY; INSULIN BLOOD LEVEL; INSULIN RELEASE; JAPANESE (PEOPLE); LABORATORY TEST; MALE; MEDICAL HISTORY; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCATCHARD PLOT; SKIN BIOPSY; SKIN INDURATION; SKIN REDNESS; TREATMENT DURATION; URTICARIA; COMPLICATION; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; EOSINOPHIL; HYPERSENSITIVITY; IMMUNOLOGY;

AGED; DIABETES MELLITUS, TYPE 2; EOSINOPHILS; HUMANS; HYPERSENSITIVITY; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN ANTIBODIES; LIRAGLUTIDE; MALE;

EID: 84982682909     PISSN: None     EISSN: 17521947     Source Type: Journal    
DOI: 10.1186/s13256-016-0994-4     Document Type: Article

References (31)

1. Ghazavi MK, Johnston GA. Insulin allergy. Clin Dermatol. 2011;29(3):300-5.
2. Heinzerling L, Raile K, Rochlitz H, Zuberbier T, Worm M. Insulin allergy: clinical manifestations and management strategies. Allergy. 2008;63(2):148-55.
3. Blanco C, Castillo R, Quiralte J, Delgado J, García I, de Pablos P, et al. Anaphylaxis to subcutaneous neutral protamine Hagedorn insulin with simultaneous sensitization to protamine and insulin. Allergy. 1996;51(6):421-4.
4. Seino Y, Yabe D. Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreas. J Diabetes Investig. 2013;4(2):108-30.
5. Kawanami D, Ito T, Watanabe Y, Kinoshita J, Sakamoto M, Isaka T, et al. Successful control of a case of severe insulin allergy with liraglutide. J Diabetes Investig. 2013;4(1):94-6.
6. Fujishiro M, Izumida Y, Takemiya S, Kuwano Y, Takamoto I, Suzuki R, Yamauchi T, Ueki K, Kadowaki T. A case of insulin allergy successfully managed using multihexamer-forming insulin degludec combined with liraglutide. Diabet Med. 2015 Oct 20. doi: 10.1111/dme.12998.
7. 131 metabolism in human subjects: demonstration of insulin binding globulin in the circulation of insulin treated subjects. J Clin Invest. 1956;35(2):170-90.
8. Iizuka K, Tomita R, Horikawa Y, Takeda J. A case of glycemic instability and insulin allergy due to anti-insulin antibodies in a patient with type 2 diabetes. Diabetol Int. 2012;3(4):233-8.
9. Yamada H, Asano T, Kusaka I, Kakei M, Ishikawa S. Type B insulin resistance syndrome with fasting hypoglycemia and postprandial hyperglycemia. Diabetol Int. 2015;6(2):144-48.
10. Blanchard C, Marc E. Rothenberg biology of the eosinophil. Adv Immunol. 2009;101:81-121.
11. Roufosse F, Weller P. Practical approach to the patient with hypereosinophilia. J Allergy Clin Immunol. 2010;126(1):39-44.
12. Nagai Y, Mori T, Abe T, Nomura G. Immediate-type allergy against human insulin associated with marked eosinophilia in type 2 diabetic patient. Endocr J Jun. 2001;48(3):311-6.
13. Uriuhara A, Morita S, Kuroda S, Fumoto M, Araki S, Aoyama N, et al. Severe insulin-resistant diabetes mellitus associated with hypereosinophilic syndrome. Intern Med. 1994;33(10):632-6.
14. Nagai T, Nagai Y, Tomizawa T, Mori M. Immediate-type human insulin allergy successfully treated by continuous subcutaneous insulin infusion. Intern Med. 1997;36(8):575-8.
15. Matheu V, Perez E, Hernández M, Díaz E, Darias R, González A, et al. Insulin allergy and resistance successfully treated by desensitisation with aspart insulin. Clin Mol Allergy. 2005;23(3):16.
16. Malaise J, Leonet J, Goffin E, Lefebvre C, Tennstedt D, Vandeleene B, et al. Pancreas transplantation for treatment of generalized allergy to human insulin in type 1 diabetes. Transplant Proc. 2005;37(6):2839.
17. Cavelti-Weder C, Muggli B, Keller C, Babians-Brunner A, Biason-Lauber A, Donath MY, et al. Successful use of omalizumab in an inadequately controlled type 2 diabetic patient with severe insulin allergy. Diabetes Care. 2012;35(6):e41.
18. Kozawa J, Inoue K, Iwamoto R, Kurashiki Y, Okauchi Y, Kashine S, et al. Liraglutide is effective in type 2 diabetic patients with sustained endogenous insulin-secreting capacity. J Diabetes Investig. 2012;3(3):294-7.
19. Meier JJ, Menge BA, Breuer TG, Müller CA, Tannapfel A, Uhl W, et al. Functional assessment of pancreatic β-cell area in humans. Diabetes. 2009;58(7):1595-603.
20. Usui R, Yabe D, Kuwata H, Fujiwara S, Watanabe K, Hyo T, et al. Retrospective analysis of safety and efficacy of insulin-to-liraglutide switch in Japanese type 2 diabetes: A caution against inappropriate use in patients with reduced β-cell function. J Diabetes Investig. 2013;4(6):585-94.
21. Jendle J, Nauck MA, Matthews DR, Frid A, Hermansen K, Düring M, et al. LEAD-2 and LEAD-3 Study Groups: Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes Obes Metab. 2009;11(12):1163-72.
22. Chen JH, Tang WH, Lee CH. Effective weight loss after treatment with a glucagon-like peptide-1 receptor agonist in a morbidly obese and diabetic patient before bariatric surgery: a case report. J Med Case Rep. 2014;8:304.
23. Uchigata Y, Kuwata S, Tokunaga K, Eguchi Y, Takayama-Hasumi S, Miyamoto M, et al. Strong association of insulin autoimmune syndrome with HLA-DR4. Lancet. 1992;339(8790):393-4.
24. Eguchi Y. Scatchard analysis of insulin autoantibodies in the insulin autoimmune syndrome (Japanese). J Tokyo Wom Med Univ. 1989;59:1296-305.
25. Hara K, Tobe K, Uchigata Y, Nakazono M, Yasuda K, Terauchi Y, et al. Antibody-mediated insulin resistance treated by cessation of insulin administration. Intern Med. 2000;39(2):143-5.
26. Tamura Y, Kimbara Y, Funatsuki S, Mabuchi S, Kodera R, Yoshimoto A, et al. A case of insulin antibody-induced glucose instability in an elderly woman with type 2 diabetes on hemodialysis, successfully ameliorated with liraglutide. Diabetol Int. 2013;4(1):71-5.
27. Hadjiyanni KA, Siminovitch JS, Drucker DJ. Glucagon-like peptide-1 receptor signaling selectively regulates murine lymphocyte proliferation and maintenance of peripheral regulatory T cells. Diabetologia. 2010;53(4):730-40.
28. Al-Badri MR, Azar ST. Effect of glucagon-like peptide-1 receptor agonists in patients with psoriasis. Ther Adv Endocrinol Metab. 2014;5(2):34-8.
29. Kim SW, Won HK, Seok H, Lee BW, Jung CH, Lee WJ, et al. High prevalence of both anti-insulin and anti-insulin receptor antibodies in Korean patients with insulin autoimmune syndrome. Diabetes Res Clin Pract Nov. 2012;98(2):e12-5.
30. Kahn CR, Flier JS, Bar RS, Archer JA, Gorden P, Martin MM, et al. The syndromes of insulin resistance and acanthosis nigricans - insulin-receptor disorders in man. N Engl J Med. 1976;294:739-45.
31. Filier JS, Kahn CR, Roth J, Bar RS. Antibodies that impair insulin receptor binding in an unusual diabetic syndrome with severe insulin resistance. Science. 1975;190:63-5.